(1)
Results support use of Agendia s genomic tests to better tailor pre-operative treatment and timing for surgery
Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint and BluePrint
, and underpin both assays pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at the 38
th Annual Miami Breast Cancer Conference.
The poster, entitled
Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients,
outlines the first age-based analyses of MammaPrint and BluePrint assays in the pre-operative setting. As expected, the data show that pCR rates varied according to molecular subtype, with MammaPrint and BluePrint accurately predicting pCR in patients of all subtypes, regard